The field is awash with recent biomarker breakthroughs, including biomarker-dependent drug approval, center stage for NGS based signatures and increasing multiplexing. It is clear the success of an efficacious, patient-centric precision medicine fundamentally rests on a solid predictive biomarker foundation. This importance only heightens as multiple drug developers fight for market share for similar targets in similar indications and healthcare providers and payers demand to see more robust clinical benefit to specific patient cohorts.
Built for biomarker, translational and clinical experts, this portion of the meeting will help you bring novel predictive biomarkers to fruition, overcoming challenges in the heterogeneity of disease, exploratory biomarker endeavours, validation of patient stratifying predictive signatures and a demonstration of clinical utility to accelerate the approval of next generation precision medicines.
Hear data-driven pre-clinical and clinical case studies across therapeutic areas and address paradigm shifts in the utilization of multi-marker signatures to ensure you, your team and your wider “precision medicine” function deliver valuable insight into patient selection and treatment decisions and prove the safety, efficacy and value of your targeted therapeutic candidates.
Key topics to be addressed in 2019:
Advancing clinical validation of predictive biomarkers
Discovering the next generation of robustly predictive biomarkers
Accelerating the translation from exploratory signature to clinical biomarker candidate
Executing biomarker-driven and diagnostic-enabled clinical trials
Improving the validation and standardization of biomarker assays to advance development & adoption